Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade

Background. Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR.Aim. To...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. F. Semiglazov, N. B. Bekkeldieva, P. V. Krivorotko, A. V. Komyakhov, R. M. Paltuev, A. I. Tseluyko, L. P. Gigolaeva, T. T. Tabagua, E. K. Zhiltsova, V. S. Apollonova, G. A. Dashyan, A. G. Kudaybergenova, V. G. Ivanov, A. A. Bozhok, D. G. Ulrikh, A. O. Gorina, T. Yu. Semiglazova
Format:	Article
Language:	Russian
Published:	ABV-press 2024-11-01
Series:	Опухоли женской репродуктивной системы
Subjects:	her2-positive breast cancer stage ii–iii neoadjuvant double her2 blockade trastuzumab + pertuzumab lapatinib + trastuzumab
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/1272
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade

Similar Items